Diuretic therapy

New England Journal of Medicine

Volumn 339, Issue 6, 1998, Pages 387-395

  Brater, D Craig ^a  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMILORIDE; BENDROFLUMETHIAZIDE; BUMETANIDE; CHLOROTHIAZIDE; CHLORTALIDONE; FUROSEMIDE; HYDROFLUMETHIAZIDE; INDAPAMIDE; LOOP DIURETIC AGENT; POLYTHIAZIDE; SPIRONOLACTONE; THIAZIDE DIURETIC AGENT; TORASEMIDE; TRIAMTERENE; TRICHLORMETHIAZIDE;

ALGORITHM; CONGESTIVE HEART FAILURE; DRUG INDUCED DISEASE; DRUG TOLERANCE; EDEMA; HUMAN; KIDNEY FAILURE; LIVER CIRRHOSIS; NEPHROTIC SYNDROME; PHARMACODYNAMICS; PRIORITY JOURNAL; REVIEW;

DIURETICS; DRUG INTERACTIONS; EDEMA; HEART FAILURE, CONGESTIVE; HUMANS; KIDNEY FAILURE; LIVER CIRRHOSIS; NEPHROTIC SYNDROME;

EID: 0032491044     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJM199808063390607     Document Type: Review

References (93)

1. Chennavasin P, Seiwell R, Brater DC, Liang WMM. Pharmacodynamic analysis of the furosemide-probenecid interaction in man. Kidney Int 1979; 6:187-95.
2. Odlind B, Beermann B. Renal tubular secretion and effects of furosemide. Clin Pharmacol Ther 1980;27:784-90.
3. Lau HSH, Shih LJ, Smith DE. Effect of probenecid on the dose-response relationship of bumetanide at steady state. J Pharmacol Exp Ther 1983;227:51-4.
4. Brater DC, Leinfelder J, Anderson SA. Clinical pharmacology of torasemide, a new loop diuretic. Clin Pharmacol Ther 1987;42:187-92.
5. Besseghir K, Rennick B. Renal tubule transport and electrolyte effects of amiloride in the chicken. J Pharmacol Exp Ther 1981;219:435-41.
6. Kau ST. Handling of triamterene by the isolated perfused rat kidney. J Pharmacol Exp Ther 1978;206:701-9.
7. Brater DC. Diuretic pharmacokinetics and pharmacodynamics. In: van Boxtel CJ, Holford NHG, Danhof M, eds. The in vivo study of drug action: principles and applications of kinetic-dynamic modelling. Amsterdam: Elsevier Science, 1992:253-75.
8. Beermann B. Aspects of pharmacokinetics of some diuretics. Acta Pharmacol Toxicol (Copenh) 1984;54:Suppl 1:17-29.
9. Pichette V, du Souich P. Role of the kidneys in the metabolism of furosemide: its inhibition by probenecid. J Am Soc Nephrol 1996;7:345-9.
10. Fuller R, Hoppel C, Ingalls ST. Furosemide kinetics in patients with hepatic cirrhosis with ascites. Clin Pharmacol Ther 1981;30:461-7.
11. Verbeeck RK, Patwardhan RV, Villeneuve JP, Wilkinson GR, Branch RA. Furosemide disposition in cirrhosis. Clin Pharmacol Ther 1982;31: 719-25.
12. Villeneuve JP, Verbeeck RK, Wilkinson GR, Branch RA. Furosemide kinetics and dynamics in patients with cirrhosis. Clin Pharmacol Ther 1986;40:14-20.
13. Traeger A, Häntze R, Penzlin M, et al. Pharmacokinetics and pharmacodynamic effects of furosemide in patients with liver cirrhosis. Int J Clin Pharmacol Ther Toxicol 1985;23:129-33.
14. Keller E, Hoppe-Seyler G, Mumm R, Schollmeyer P. Influence of hepatic cirrhosis and end-stage renal disease on pharmacokinetics and pharmacodynamics of furosemide. Eur J Clin Pharmacol 1981;20:27-33.
15. Davies DL, Lant AF, Millard NR, Smith AJ, Ward JW, Wilson GM. Renal action, therapeutic use, and pharmacokinetics of the diuretic bumetanide. Clin Pharmacol Ther 1974;15:141-55.
16. Holazo AA, Colburn WA, Gustafson JH, Young RL, Parsonnet M. Pharmacokinetics of bumetanide following intravenous, intramuscular, and oral administrations to normal subjects. J Pharm Sci 1984;73:1108-13.
17. Brater DC, Chennavasin P, Day B, Burdette A, Anderson S. Bumetanide and furosemide. Clin Pharmacol Ther 1983;34:207-13.
18. Schwartz S, Brater DC, Pound D, Greene PK, Kramer WG, Rudy D. Bioavailability, pharmacokinetics, and pharmacodynamics of torsemide in patients with cirrhosis. Clin Pharmacol Ther 1993;54:90-7.
19. Smith AJ, Smith RN. Kinetics and bioavailability of two formulations of amiloride in man. Br J Pharmacol 1973;48:646-9.
20. Sahn H, Reuter K, Mutschler E, Gerok W, Knauf H. Pharmacokinetics of amiloride in renal and hepatic disease. Eur J Clin Pharmacol 1987; 33:493-8.
21. Knauf H, Möhrke W, Mutschler E. Delayed elimination of triamterene and its active metabolite in chronic renal failure. Eur J Clin Pharmacol 1983;24:453-6.
22. Villeneuve JP, Rocheleau F, Raymond G. Triamterene kinetics and dynamics in cirrhosis. Clin Pharmacol Ther 1984;35:831-7.
23. Ochs HR, Greenblatt DJ, Bodem G, Smith TW. Spironolactone. Am Heart J 1978;96:389-400.
24. Overdiek HWPM, Hermens WAJJ, Merkus FWHM. New insights into the pharmacokinetics of spironolactone. Clin Pharmacol Ther 1985;38: 469-74.
25. Gehr TWB, Rudy DW, Matzke GR, Kramer WG, Sica DA, Brater DC. The pharmacokinetics of intravenous and oral torsemide in patients with chronic renal insufficiency. Clin Pharmacol Ther 1994;56:31-8.
26. Vargo DL, Kramer WG, Black PK, Smith WB, Serpas T, Brater DC. Bioavailability, pharmacokinetics, and pharmacodynamics of torsemide and furosemide in patients with congestive heart failure. Clin Pharmacol Ther 1995;57:601-9.
27. Murray MD, Ferguson JA, Bennett SJ, et al. Fewer hospitalizations for heart failure by using a completely and predictably absorbed loop diuretic. J Gen Intern Med 1998;13:Suppl:18. abstract.
28. Chaturvedi PR, O'Donnell JP, Nicholas JM, Shoenthal DR, Waters DH, Gwilt PR. Steady state absorption kinetics and pharmacodynamics of furosemide in congestive heart failure. Int J Clin Pharmacol Ther Toxicol 1987;25:123-8.
29. Van Meyel JJM, Gerlag PGG, Smits P, et al. Absorption of high dose furosemide (frusemide) in congestive heart failure. Clin Pharmacokinet 1992;22:308-18.
30. Bailie GR, Grennan A, Waldek S. Bioavailability of bumetanide in grossly oedematous patients. Clin Pharmacokinet 1987;12:440-3.
31. Brater DC, Day B, Burdette A, Anderson S. Bumetanide and furosemide in heart failure. Kidney Int 1984;26:183-9.
32. Vasko MR, Cartwright DB, Knochel JP, Nixon JV, Brater DC. Furosemide absorption altered in decompensated congestive heart failure. Ann Intern Med 1985;102:314-8.
33. Wilcox CS, Mitch WE, Kelly RA, et al. Response of the kidney to furosemide. I. Effects of salt intake and renal compensation. J Lab Clin Med 1983;102:450-8.
34. Ferguson JA, Sundblad KJ, Becker PK, Gorski JC, Rudy DW, Brater DC. Role of duration of diuretic effect in preventing sodium retention. Clin Pharmacol Ther 1997;62:203-8.
35. Hammarlund MM, Odlind B, Paalzow LK. Acute tolerance to furosemide diuresis in humans: pharmacokinetic-pharmacodynamic modeling. J Pharmacol Exp Ther 1985;233:447-53.
36. Wakelkamp M, Alván G, Gabrielsson J, Paintaud G. Pharmacodynamic modeling of furosemide tolerance after multiple intravenous administration. Clin Pharmacol Ther 1996;60:75-88.
37. Almeshari K, Ahlstrom NG, Capraro FE, Wilcox CS. A volume-independent component to postdiuretic sodium retention in humans. J Am Soc Nephrol 1993;3:1878-83.
38. Kelly RA, Wilcox CS, Mitch WE, et al. Response of the kidney to furosemide. II. Effect of captopril on sodium balance. Kidney Int 1983;24: 233-9.
39. Wilcox CS, Guzman NJ, Mitch WE, et al. Na+, K+, and BP homeostasis in man during furosemide: effects of prazosin and captopril. Kidney Int 1987;31:135-41.
40. Petersen JS, Shalmi M, Abildgaard U, Christensen NJ, Christensen S. Renal effects of α-adrenoceptor blockade during furosemide diuresis in conscious rats. Pharmacol Toxicol 1992;70:3-12.
41. Kaissling B, Stanton BA. Adaptation of distal tubule and collecting duct to increased sodium delivery. I. Ultrastructure. Am J Physiol 1988; 255:F1256-F1268.
42. Stanton BA, Kaissling B. Adaptation of distal tubule and collecting duct to increased Na delivery. II. Na+ and K+ transport. Am J Physiol 1988;255:F1269-F1275.
43. Ellison DH, Velázquez H, Wright FS. Adaptation of the distal convoluted tubule of the rat: structural and functional effects of dietary salt intake and chronic diuretic infusion. J Clin Invest 1989;83:113-26.
44. Loon NR, Wilcox CS, Unwin RJ. Mechanism of impaired natriuretic response to furosemide during prolonged therapy. Kidney Int 1989;36:682-9.
45. Kobayashi S, Clemmons DR, Nogami H, Roy AK, Venkatachalam MA. Tubular hypertrophy due to work load induced by furosemide is associated with increases of IGF-1 and IGFBP-1. Kidney Int 1995;47:818-28.
46. Ellison DH. The physiologic basis of diuretic synergism: its role in treating diuretic resistance. Ann Intern Med 1991;114:886-94.
47. Sica DA, Gehr TWB. Diuretic combinations in refractory oedema states: pharmacokinetic-pharmacodynamic relationships. Clin Pharmacokinet 1996;30:229-49.
48. Epstein M, Lepp BA, Hoffman DS, Levinson R. Potentiation of furosemide by metolazone in refractory edema. Curr Ther Res 1977;21:656-67.
49. Olesen KH, Sigurd B. The supra-additive natriuretic effect addition of quinethazone or bendroflumethiazide during long-term treatment with furosemide and spironolactone: permutation trial tests in patients with congestive heart failure. Acta Med Scand 1971;190:233-40.
50. Voelker JR, Cartwright-Brown D, Anderson S, et al. Comparison of loop diuretics in patients with chronic renal insufficiency. Kidney Int 1987; 32:572-8.
51. van Olden RW, van Meyel JJM, Gerlag PGG. Sensitivity of residual nephrons to high dose furosemide described by diuretic efficiency. Eur J Clin Pharmacol 1995;47:483-8.
52. Rudy DW, Gehr TWB, Matzke GR, Kramer WG, Sica DA, Brater DC. The pharmacodynamics of intravenous and oral torsemide in patients with chronic renal insufficiency. Clin Pharmacol Ther 1994;56:39-47.
53. Gallagher KL, Jones JK. Furosemide-induced ototoxicity. Ann Intern Med 1979;91:744-5.
54. Gerlag PGG, van Meijel JJM. High-dose furosemide in the treatment of refractory congestive heart failure. Arch Intern Med 1988;148:286-91.
55. Rudy DW, Voelker JR, Greene PK, Esparza FA, Brater DC. Loop diuretics for chronic renal insufficiency: a continuous infusion is more efficacious than bolus therapy. Ann Intern Med 1991;115:360-6.
56. Wollam GL, Tarazi RC, Bravo EL, Dustan HP. Diuretic potency of combined hydrochlorothiazide and furosemide therapy in patients with azotemia. Am J Med 1982;72:929-38.
57. Fliser D, Schröter M, Neubeck M, Ritz E. Coadministration of thiazides increases the efficacy of loop diuretics even in patients with advanced renal failure. Kidney Int 1994;46:482-8.
58. Knauf H, Mutschler E. Diuretic effectiveness of hydrochlorothiazide and furosemide alone and in combination in chronic renal failure. J Cardiovasc Pharmacol 1995;26:394-400.
59. Inoue M, Okajima K, Itoh K, et al. Mechanism of furosemide resistance in analbuminemic rats and hypoalbuminemic patients. Kidney Int 1987;32:198-203.
60. Rane A, Villeneuve JP, Stone WJ, Nies AS, Wilkinson GR, Branch RA. Plasma binding and disposition of furosemide in the nephrotic syndrome and in uremia. Clin Pharmacol Ther 1978;24:199-207.
61. Keller E, Hoppe-Seyler G, Schollmeyer P. Disposition and diuretic effect of furosemide in the nephrotic syndrome. Clin Pharmacol Ther 1982; 32:442-9.
62. Green TP, Mirkin BL. Resistance of proteinuric rats to furosemide: urinary drug protein binding as a determinant of drug effect. Life Sci 1980; 26:623-30.
63. Idem. Furosemide disposition in normal and proteinuric rats: urinary drug-protein binding as a determinant of drug excretion. J Pharmacol Exp Ther 1981;218:122-7.
64. Kirchner KA, Voelker JR, Brater DC. Intratubular albumin blunts the response to furosemide - a mechanism for diuretic resistance in the nephrotic syndrome. J Pharmacol Exp Ther 1990;252:1097-101.
65. Idem. Binding inhibitors restore furosemide potency in tubule fluid containing albumin. Kidney Int 1991;40:418-24.
66. Idem. Tubular resistance to furosemide contributes to the attenuated diuretic response in nephrotic rats. J Am Soc Nephrol 1992;2:1201-7.
67. Nakahama H, Orita Y, Yamazaki M, et al. Pharmacokinetic and pharmacodynamic interactions between furosemide and hydrochlorothiazide in nephrotic patients. Nephron 1988;49:223-7.
68. Shear L, Ching S, Gabuzda GJ. Compartmentalization of ascites and edema in patients with hepatic cirrhosis. N Engl J Med 1970;282:1391-6.
69. Greither A, Goldman S, Edelen JS, Benet LZ, Cohn K. Pharmacokinetics of furosemide in patients with congestive heart failure. Pharmacology 1979;19:121-31.
70. Andreasen F, Mikkelsen E. Distribution, elimination and effect of furosemide in normal subjects and in patients with heart failure. Eur J Clin Pharmacol 1977;12:15-22.
71. Perez J, Sitar DS, Ogilvie RI. Kinetic disposition and diuretic effect of frusemide in acute pulmonary oedema. Br J Clin Pharmacol 1980;9: 471-8.
72. Brater DC, Chennavasin P, Seiwell R. Furosemide in patients with heart failure: shift in dose-response curves. Clin Pharmacol Ther 1980;28: 182-6.
73. Oster JR, Epstein M, Smoller S. Combined therapy with thiazide-type and loop diuretic agents for resistant sodium retention. Ann Intern Med 1983;99:405-6.
74. Alexander WD, Branch RA, Levine DF, Hartog M. The urinary sodium: potassium ratio and response to diuretics in resistant oedema. Postgrad Med J 1977;53:117-21.
75. Van Vliet AA, Donker AJM, Nauta JJP, Verheugt FWA. Spironolactone in congestive heart failure refractory to high-dose loop diuretic and low-dose angiotensin-converting enzyme inhibitor. Am J Cardiol 1993;71: 21A-28A.
76. Maren TH. Carbonic anhydrase inhibition. IX. Augmentation of the renal effect of meralluride by acetazolamide. J Pharmacol Exp Ther 1958; 123:311-5.
77. Rodicio JL, Hernando L. Effects and interactions of furosemide and acetazolamide on tubular function in rat kidney. Rev Esp Fisiol 1977;33: 113-8.
78. Gibson DG, Marshall JC, Lockey E. Assessment of proximal tubular sodium reabsorption during water diuresis in patients with heart disease. Br Heart J 1970;32:399-405.
79. Earley LE, Martino JA. Influence of sodium balance on the ability of diuretics to inhibit tubular reabsorption: a study of factors that influence renal tubular sodium reabsorption in man. Circulation 1970;42:323-34.
80. Brater DC, Kaojarern S, Chennavasin P. Pharmacodynamics of the diuretic effects of aminophylline and acetazolamide alone and combined with furosemide in normal subjects. J Pharmacol Exp Ther 1983;227:92-7.
81. Szerlip HM. Renal-dose dopamine: fact and fiction. Ann Intern Med 1991;115:153-4.
82. Denton MD, Chertow GM, Brady HR. "Renal-dose" dopamine for the treatment of acute renal failure: scientific rationale, experimental studies and clinical trials. Kidney Int 1996;50:4-14.
83. Chertow GM, Sayegh MH, Allgren RL, Lazarus JM. Is the administration of dopamine associated with adverse or favorable outcomes in acute renal failure? Am J Med 1996;101:49-53.
84. Vargo DL, Brater DC, Rudy DW, Swan SK. Dopamine does not enhance furosemide-induced natriuresis in patients with congestive heart failure. J Am Soc Nephrol 1996;7:1032-7.
85. Warren SE, Blantz RC. Mannitol. Arch Intern Med 1981;141:493-7.
86. Borges HF, Hocks J, Kjellstrand CM. Mannitol intoxication in patients with renal failure. Arch Intern Med 1982;142:63-6.
87. Sheffield PA, Turner JS. Ototoxic drugs: a review of clinical aspects, histopathologic changes and mechanisms of action. South Med J 1971;64: 359-63.
88. Cooperman LB, Rubin IL. Toxicity of ethacrynic acid and furosemide. Am Heart J 1973;85:831-4.
89. Rose LI, Underwood RH, Newmark SR, Kisch ES, Williams GH. Pathophysiology of spironolactone-induced gynecomastia. Ann Intern Med 1977;87:398-403.
90. Brater DC. Drug-induced electrolyte disorders and use of diuretics. In: Kokko JP, Tannen RL, eds. Fluids and electrolytes. 3rd ed. Philadelphia: W.B. Saunders, 1996:693-728.
91. Chennavasin P, Seiwell R, Brater DC. Pharmacokinetic-dynamic analysis of the indomethacin-furosemide interaction in man. J Pharmacol Exp Ther 1980;215:77-81.
92. Kaojarern S, Chennavasin P, Anderson S, Brater DC. Nephron site of effect of nonsteroidal anti-inflammatory drugs on solute excretion in humans. Am J Physiol 1983;244:F134-F139.
93. Waldorff S, Anderson JD, Heeboll-Nielsen N, et al. Spironolactone-induced changes in digoxin kinetics. Clin Pharmacol Ther 1978;24:162-7.